Mineralys Therapeutics (MLYS) Stock Forecast & Price Target

$12.34 +0.51 (+4.31%)

(As of 12/20/2024 05:16 PM ET)

Mineralys Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Based on 3 Wall Street analysts who have issued ratings for Mineralys Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for MLYS.

Consensus Price Target

$30.00
143.11% Upside

According to the 3 analysts' twelve-month price targets for Mineralys Therapeutics, the average price target is $30.00. The highest price target for MLYS is $30.00, while the lowest price target for MLYS is $30.00. The average price target represents a forecasted upside of 143.11% from the current price of $12.34.

Get the Latest News and Ratings for MLYS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Mineralys Therapeutics and its competitors.

MLYS Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$30.00	$30.00	$30.00	$36.00
Forecasted Upside	143.11% Upside	152.74% Upside	156.19% Upside	344.99% Upside
Consensus Rating	Buy	Buy	Buy	Buy

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

MLYS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MLYS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Mineralys Therapeutics Stock vs. The Competition

Type	Mineralys Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	143.11% Upside	25,828.57% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent MLYS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	HC Wainwright 2 of 5 stars	M. Caufield Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00	+101.07%
4/2/2024	The Goldman Sachs Group 2 of 5 stars		Initiated Coverage	Buy	$30.00	+130.24%
3/26/2024	Lifesci Capital 2 of 5 stars	R. Katkhuda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$38.00 ➝ $37.00	+196.00%
3/7/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
3/7/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$27.00	+42.41%
3/7/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$32.00	+68.78%
3/7/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$39.00	+105.70%
3/7/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$45.00	+137.34%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:29 PM ET.

MLYS Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Mineralys Therapeutics is $30.00, with a high forecast of $30.00 and a low forecast of $30.00.
: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MLYS shares.
: According to analysts, Mineralys Therapeutics's stock has a predicted upside of 143.11% based on their 12-month stock forecasts.
: Mineralys Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days.
: Analysts like Mineralys Therapeutics more than other "medical" companies. The consensus rating for Mineralys Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MLYS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NASDAQ:MLYS) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Stock Forecast & Price Target